Alumis Inc.

ALMS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023
Revenue $24.1M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $386.0M $265.6M $137.7M
SG&A Expense $91.9M $35.2M $20.5M
Operating Income $-453.8M $-300.8M $-158.2M
Operating Margin -1,886.9%
Interest Expense
Pretax Income $-251.9M $-294.2M
Income Tax Expense $-8.6M $0 $0
Net Income $-243.3M $-294.2M $-155.0M
Net Margin -1,011.7%
EPS (Basic) $-2.86 $-3.46 $-1.85
EPS (Diluted) $-2.86 $-3.46 $-1.85
Shares Outstanding (Basic) 85.0M 85.0M 83.9M
Shares Outstanding (Diluted) 85.0M 85.0M 83.9M
Dividends Per Share